Michael Grissinger

Michael Grissinger brings decades of experience in business development, strategy, and pharmaceutical licensing leadership roles at global pharmaceutical companies. He retired from Johnson & Johnson in January 2018 after a 22- year career. During his tenure at Johnson & Johnson, Mr. Grissinger held various positions including Vice President Mergers and Acquisitions, Divestitures, and Head, Immunology Business Development from April 2016 to January 2018, Vice President, Corporate Development for Pharmaceuticals from January 2014 to March 2016, and Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. While at Johnson & Johnson, Mr. Grissinger led transactions and teams across a broad span od deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the boards of Akari Therapeutics, Plc (AKTX), and Atrin Pharmaceuticals. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an MBA from Temple University- Fox School of Business.